Journal Articles

  1. & Ethnic disparities in the uptake of pharmacy services. The Pharmaceutical Journal 297(7893)
  2. & New/emerging psychoactive substances and associated psychopathological consequences. Psychological Medicine, 1-13.
  3. & Method development for the determination of elements in Hypericum perforatum L. (St John's wort) herb and preparations using inductively coupled plasma–optical emission spectroscopy and microwave digestion. Journal of Pharmacy and Pharmacology 71(1), 38-45.
  4. & Assessing the 2004–2018 Fentanyl Misusing Issues Reported to an International Range of Adverse Reporting Systems. Frontiers in Pharmacology 10
  5. & An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions. International Journal of Neuropsychopharmacology 22(4), 270-277.
  6. & New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues. Current Addiction Reports
  7. & Exploration of the Use of New Psychoactive Substances by Individuals in Treatment for Substance Misuse in the UK. Brain Sciences 8(4), 58
  8. & Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. Brain Sciences 8(4), 73
  9. & Psychedelic Fauna for Psychonaut Hunters: A Mini-Review. Frontiers in Psychiatry 9
  10. & Detection of newly emerging psychoactive substances using Raman spectroscopy and chemometrics. RSC Advances 8(56), 31924-31933.
  11. & Identification of new psychoactive substances (NPS) using handheld Raman spectroscopy employing both 785 and 1064 nm laser sources. Forensic Science International 273, 113-123.
  12. & Intended and unintended use of cathinone mixtures. Human Psychopharmacology: Clinical and Experimental 32(3), e2598
  13. New psychoactive substances: a public health issue. International Journal of Pharmacy Practice 25(5), 323-325.
  14. & Drowning in diversity? A systematic way of clustering and selecting a representative set of new psychoactive substances. RSC Advances 7(84), 53181-53191.
  15. & The “Endless Trip” among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review. Frontiers in Psychiatry 8
  16. & Identification of new psychoactive substances using Raman spectroscopy: handheld and computational approaches. Research and Advances in Psychiatry 2(3)
  17. & Survey of knowledge of legal highs (novel psychoactive substances) amongst London pharmacists. Drugs and Alcohol Today 15(2), 93-99.
  18. Discovering how to identify new psychoactive substances through PhD research. The Pharmaceutical Journal
  19. Pharmacy consultation outcomes during a lung cancer awareness campaign.
  20. & Analysis of ‘legal high’ substances and common adulterants using handheld spectroscopic techniques. Analytical Methods 7(2), 736-746.
  21. Presence of metals in herbal extracts. , 536-539.

Book Chapters

  1. & Synthetic Cathinones—Prevalence and Motivations for Use. In Synthetic Cathinones: Current Topics in Neurotoxicity, vol 12. Springer, Cham. (pp. 153-189). Springer, Cham.
  2. & New Psychoactive Substances. In Wing Tang (Ed.), Medicines, Ethics and Practice. The Professional Guide for Pharmacists. UK: Royal Pharmaceutical Society.

Conference Contributions

  1. (2016). Chemical evaluation of internet products containing new psychoactive substances to investigate supply/ distribution chains.

Other Research Outputs

  1. & Updates on The In-Field Detection of New Psychoactive Substances. Research and Advances in Psychiatry 6(1)
  2. & GC-MS data for mexedrone.
  3. (2016). Substance use and misuse.
  4. Community Pharmacist interventions and improved COPD management. npj Primary Care Respiratory Medicine
  5. (2015). Written evidence to the psychoactive substances inquiry.